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a  b  s  t  r  a  c  t
Experiencing  psychosocial  stress  in  early  life,  such  as social  isolation  stress  (SIS),  is  known  to  have negative
enduring  effects on the  development  of  the  brain  and  behavior.  In  addition  to anxiety  and  depressive-like
behaviors,  we  previously  showed  that juvenile  SIS  increases  susceptibility  to  pentylenetetrazole  (PTZ)-
induced  seizures  in  mice through  enhancing  the nitrergic  system  activity  in the  hippocampus.  In this
study,  we  investigated  the  possible  involvement  of N-methyl-d-aspartate  (NMDA)  receptors  in procon-
vulsant  effects  of juvenile  SIS.  Applying  4  weeks  of  SIS  to  juvenile  male  mice  at postnatal  day  21–23,  we
observed  an increased  susceptibility  to  PTZ as well  as  anxiety  and depressive-like  behaviors  in adult  mice.
Intraperitoneal  (i.p.) administration  of  NMDA  receptor  antagonists,  MK-801  (0.05  mg/kg)  and  ketamine
(0.5  mg/kg),  reversed  the  proconvulsant  effects  of  SIS  in Isolated  (and  not  social)  housed  animals.  Co-
administration  of non-effective  doses  of  nitric  oxide  synthase  (NOS)  inhibitors,  7NI  (25  mg/kg)  and
L-NAME  (10 mg/kg),  with  NMDA  receptor  antagonists,  MK-801  (0.01  mg/kg)  and  ketamine  (0.1  mg/kg)
attenuated  the  proconvulsant  effects  of  juvenile  SIS  only  in  isolated  housed  mice.  Also,  using  real  time
RT-PCR,  we showed  that  hippocampal  upregulation  of  NR2B subunit  of NMDA  receptor  may  play  a  crit-
ical  role in proconvulsant  effects  of juvenile  SIS  by  dysregulation  of NMDA/NO  pathway.  In conclusion,
results  of  present  study  revealed  that  experiencing  SIS  during  adolescence  predisposes  the  co-occurrence
of seizure  disorders  with  psychiatric  comorbidities  and also,  alteration  of  NMDA  receptor  structure  and
function  in hippocampus  plays  a role in  proconvulsant  effects  of  juvenile  SIS through  enhancing  the
NMDA/NO  pathway.
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Social isolation, as a chronic stress, is a determinant psychosocial
factor which has profound effects on the social functioning, qual-
ity of life and severity of disease in epileptic patients (Suurmeijer
et al., 2001; McCagh et al., 2009). Although large body of evidence
indicates that psychosocial stressors are accompanied by high mor-
bidity and severity of disease in patients with epilepsy, there are
few studies that have directly focused on the underlying mecha-
nisms by which chronic stress increases seizure risk and occurrence
(Yuen et al., 2007; Maguire and Salpekar, 2013). In this regard,
clinical and preclinical data have shown that social isolation stress
(SIS) increases the risk of seizure susceptibility in both human and
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odents (Yuen et al., 2007; Chadda and Devaud, 2004; Matsumoto
t al., 2003).
Experiencing juvenile SIS (as a valid animal model of chronic
tress) has been reported to induce diversity of neurobehavioral
nd developmental changes in the brain (Fone and Porkess, 2008).
xposure to chronic stress mostly in the developmental stages of
ife is known to make remarkable neuroplastical alterations such
s changes in receptors function and structure that affect excita-
ory and inhibitory synaptic neurotransmission in several regions
f the brain (Maguire and Salpekar, 2013; Salzberg et al., 2007). In
his context, N-methyl-d-aspartate (NMDA) receptors have gained
pecial attention because of their involvement in the pathophysil-
gy of a majority of brain diseases including seizure disorders
Kalia et al., 2008; Waxman and Lynch, 2005). It has been well
ocumented that stress-induced increase in glutamatergic neuro-
ransmission leads to excitotoxicity through activation of NMDA
eceptors and hence, causes brain injury (Olivenza et al., 2000;
hasemi et al., 2014). Previous data showed that both NMDA recep-
or antagonists and nitric oxide synthase (NOS) inhibitors not only
re able to reduce detrimental impacts of stress on the brain but also
xerts anticonvulsant properties (Ghasemi and Schachter, 2011;
anach et al., 2011; Hardingham, 2009). On the other hand, juve-
ile SIS has been reported to alter excito-inhibitory balance by
hanging the regulation of NMDA receptors and nitrergic system
n cortico-limbic areas (Petrovszki et al., 2013; Matsumoto et al.,
007; Zlatkovic´ et al., 2014). Surprisingly, underlying mechanisms
y which SIS primes seizure vulnerability have not been well stud-
ed. We recently showed that experiencing SIS in the adolescence
s associated with enhanced seizure susceptibility through activa-
ion of nitrergic system in the hippocampus (Amiri et al., 2014).
lso, we previously demonstrated that nitrergic system and NMDA
eceptors contribute to development of anxiety and depressive like
ehaviors in adult mice following juvenile SIS (Amiri et al., 2015a;
aj-Mirzaian et al., 2015a).
In this study, we aimed to investigate whether NMDA receptors
ontribute to proconvulsant effect of juvenile SIS. Also, we inves-
igated the possible interaction between the NMDA receptors and
itrergic system in the hippocampus of stressed animals to ﬁnd a
echanism through which juvenile SIS exerts its negative effects.
. Materials and methods
.1. Animals
Male NMRI mice (Pasteur Institute, Tehran, Iran), weighing
0–12 g and in the postnatal state (PND: 21–23) were housed
or 4 weeks under two  different conditions: (1) social condition
SC) and (2) isolated condition (IC). Socially conditioned ani-
als were housed in groups (6 mice per cage: 25 × 25 × 15 cm)
hile IC mice were housed individually in Plexiglas boxes
24 × 17 × 12 cm)  under standard laboratory conditions (free access
o food and water, temperature: 22 ± 2 ◦C, humidity: 50 ± 10% and
2-h light–dark cycle). All procedures in this work were carried out
n accordance with the National Institutes of Health (NIH) Guide for
he Care and Use of Laboratory Animals (NIH publication # 80-23)
nd institutional guidelines for animal care and use (Department
f Pharmacology, School of Medicine, TUMS).
.2. Forced swimming test (FST)
We  used FST as a behavioral test in order to evaluate the effects
f juvenile SIS on behavioral despair of animals (Haj-Mirzaian
t al., 2014; Russo et al., 2013; Cryan and Holmes, 2005). In brief,
ice were individually placed in an open glass cylinder (diameter:
0 cm,  height: 25 cm)  containing 19 cm water (23 ± 1 ◦C). Mice werelletin 121 (2016) 158–168 159
allowed to swim for 6 min, and the immobility time was recorded
during the last 4 min of the test. Immobility behavior was consid-
ered when the animal remained ﬂoating motionless in the water
and made only those necessary movements to keep its head above
water.
2.3. Splash test
Splash test was used in order to investigate the possible effect
of SIS on behaviors related to motivational and self-care difﬁcul-
ties in animals. In this test, grooming behavior of mice, which can
be considered as an indirect measure of palatable solution intake
was measured. A 10% sucrose solution was  squirted on the dorsal
coat of each animal in the home cage. In case of SC mice, ani-
mals were housed individually for 24 h before the test. Behaviors of
mice were videotaped for 5 min  and grooming activity time includ-
ing nose/face grooming, head washing, and body grooming were
scored by an experimenter who  was blind to the treatment condi-
tions (Haj-Mirzaian et al., 2015b; Nollet et al., 2013).
2.4. Elevated plus maze (EPM)
This test was used in order to evaluate the effects of SIS on
anxiety-like behaviors in mice (Amiri et al., 2015b). The EPM appa-
ratus was made of black opaque Plexiglas and consisted of two
open (30 × 5 cm)  and closed (30 × 5 × 15 cm)  arms, which were
connected by a platform area (5 × 5 cm). Testing room was  dimly
illuminated and animals were individually placed in the center
of the EPM facing to closed arm and each behavioral session was
videotaped for a 5 min  period. The total time spent in the open arms
as well as number of entries into the open arms were recorded over
a period of 5 min  and reported as percentages (Table 1).
2.5. Drugs and treatments
The following drugs were used in this study: pentylenetetrazole
(PTZ), NG-nitro-l-arginine methyl ester (L-NAME), 7-nitroindazole
(7NI), MK-801, and ketamine. Drugs were purchased from Sigma
(UK) and were dissolved in saline (except for 7-NI which was  sus-
pended in Tween80 1%) and were administered in the volume of
5 ml/kg animal weights. In order to investigate the seizure suscepti-
bility in experimental animals, we  administered PTZ intravenously
(0.5%, i.v.) and all other drugs intraperitoneally (i.p.).
2.6. Determination of clonic and tonic seizure threshold
In order to measure SIS-induced alterations in the seizure sus-
ceptibility, we  assessed both clonic and tonic seizure thresholds in
mice using the method that was  previously described (Amiri et al.,
2014; Amini-Khoei et al., 2015) with little modiﬁcations. Brieﬂy, a
winged infusion set (30 gauge) was used to infuse the PTZ (0.5%) at
a constant rate of 1 ml/min (using NE 1000, New Era Pump System,
Inc.) into the tail vein of the freely moving subjects. Each animal
behavior was videotaped by a camera and observed seizure signs
were reported as (1) onset of clonus seizures (clonus threshold)
characterized by forelimbs clonus (following by full clonus of the
body and loss of righting ability) and (2) tonic hind limb exten-
sion (tonic threshold). Infusion was halted at the appearance of
tonic hind limb extension, characterized by extreme muscle rigid-
ity starting at the head and progressing along the body with full
extended hind limbs ﬁnally. The minimal dose of PTZ (mg/kg mouse
weight) required for inducing seizure signs was considered as the
indices of both seizure thresholds. As such, seizure threshold is
dependent on the dose and time of PTZ administration.
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Table 1
Experimental groups of the study: housing conditions (start and endpoint from PND), treatments, and number of animals in each experimental group were illustrated.
Groups Conditions (PND start-end) Treatments Numb. Behavioral tests
(PND time)
Molecular tests
SC1 4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 8–9 EPM (Khan et al.,
2015) & FST (Jones
et al., 2014)
–
SC2  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 8 Splash test (Jones
et al., 2014)
–
SC3  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC4  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Saline (5 ml/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC5  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Tween80 (5 ml/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC6  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Ketamine
(0.1 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC7  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Ketamine
(0.5 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC8  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
MK-801
(0.01 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
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Table 1 (Continued)
Groups Conditions (PND start-end) Treatments Numb. Behavioral tests
(PND time)
Molecular tests
SC9 4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
MK-801
(0.05 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC10  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME (10 mg/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC11  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
7-NI (15 mg/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC12  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + Ketamine
(0.1 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC13  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + MK-
801
(0.01 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC14  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + Ketamine
(0.1 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC15  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + MK-
801
(0.01 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
SC16  4 weeks of SC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 3 – NR2A and NR2B
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Table 1 (Continued)
Groups Conditions (PND start-end) Treatments Numb. Behavioral tests
(PND time)
Molecular tests
IC1 4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 8–9 EPM (Khan et al.,
2015) & FST (Jones
et al., 2014)
–
IC2  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 8 Splash test (Jones
et al., 2014)
–
IC3  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC4  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Saline (5 ml/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC5  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Tween80 (5 ml/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC6  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Ketamine
(0.1 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC7  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
Ketamine
(0.5 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC8  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and  Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
MK-801
(0.01 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
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Table 1 (Continued)
Groups Conditions (PND start-end) Treatments Numb. Behavioral tests
(PND time)
Molecular tests
IC9 4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
MK-801
(0.05 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC10  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME (10 mg/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC11  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
7-NI (15 mg/kg) 6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC12  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + Ketamine
(0.1 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC13  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + MK-
801
(0.01 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC14  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + Ketamine
(0.1 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC15  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
L-NAME
(10 mg/kg) + MK-
801
(0.01 mg/kg)
6–8 PTZ-seizure model
(Jones et al., 2014)
–
IC16  4 weeks of IC (Haj-Mirzaian et al., 2015a,b, 2014; Russo et al., 2013; Cryan and Holmes, 2005;
Nollet et al., 2013; Amiri et al., 2015b; Amini-Khoei et al., 2015; Schmittgen and Livak, 2008;
Blanchard et al., 2001; MacKenzie and Maguire, 2015; Lupien et al., 2009; Huang, 2014; Andersen
and Teicher, 2008; Zˇiburkus et al., 2013; Zhao et al., 2009; Gan et al., 2014; Frasca et al., 2011;
Fujikawa, 2005; Chang et al., 2015; Toua et al., 2010; Kawasaki et al., 2011; Turnock Jones et al.,
2009; Ewald et al., 2008; Di Maio et al., 2013; Forder and Tymianski, 2009; Watanabe et al., 2013;
Przegalin˜ski et al., 1996; Sattler et al., 1999; Khan et al., 2015)
– 3 – NR2A and NR2B
gene expression
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ogrin2a ACGTGACAGAACGCGAACTT TCAGTGCGGTTCATCAATAACG
grin2b CAGCAAAGCTCGTTCCCAAAA GTCAGTCTCGTTCATGGCTAC
Hprt1 TGCTCGAGATGTGATGAAGG AAGCAGATGGCCACAGAACT
.7. Real-time RT-PCR analysis for NMDA receptor subunits
Animals were sacriﬁced under mild anesthesia and hippocampi
ere dissected on ice-cold surface and immediately homogenized
ith Trizol (Invitrogen) in order to isolate the total RNA from
he samples. Changes in mRNA levels of desired genes were mea-
ured by qRT-PCR after reverse transcription of 1 g of RNA from
ach sample using PrimeScript RT reagent kit (Takara Bio, Inc.,
tsu, Japan). qRT-PCR was  performed on a light cycler instrument
Roche Diagnostics, Mannheim, Germany) using SYBR Premix Ex
aq technology (Takara Bio). Thermal cycling conditions involved
n initial activation step for 30 s at 95 ◦C followed by 45 cycles
ncluding a denaturation step for 5 s at 95 ◦C and a combined
nnealing/extension step for 20 s at 60 ◦C. Melting curve analysis
as applied to validate whether all primers yielded a single PCR
roduct. The primers used for NR2A and NR2B genes expression
grin2a and grin2b) are listed in Table 2. Hypoxanthine phosphori-
osyl transferase1 (hprt1) was ampliﬁed as normalizer and the fold
hange in expression of each target mRNA relative to hprt1 was
alculated on the basis of 2 − ct relative expression formulas
Schmittgen and Livak, 2008).
.8. Experimental design
To determine whether juvenile SIS was able to provoke behav-
oral abnormalities in adult mice, both SC and IC mice were
ubjected to the behavioral tests including FST, splash test and
PM, after 4 weeks exposure to different housing conditions. Also,
e evaluated the possible effect of SIS on clonic and tonic seizure
hreshold using intravenous PTZ-induced seizures in animals. In
nother experimental design, we investigated the possible effect
f NMDA receptor antagonists on proconvulsant effect of SIS. In
his regard, we treated both SC and IC mice with ketamine (0.1 and
.5 mg/kg, i.p., 60 min  before PTZ seizure test) and MK-801 (0.01
nd 0.05 mg/kg, i.p., 60 min  before PTZ seizure test).
In the next step, we evaluated the possible role of nitrergic
ystem on the anti/proconvulsant effect of NMDA receptor antag-
nists. In this regard, we treated both SC and IC mice with
on-effective doses of NMDA antagonists which were obtained
rom the last parts of the study and either of the following drugs:
-NAME (10 mg/kg, i.p., 45 min  before PTZ seizure test) and 7-NI
15 mg/kg, i.p., 45 min  before PTZ seizure test). Doses of each drug
ere chosen according to the pilot treatments which were pub-
ished in our previous studies (Amiri et al., 2014). To exclude the
ossible effect of vehicle administration, SC and IC groups were
njected with 5 ml/kg sterile physiological saline and Tween80 1%.
e also investigated the NR2A and NR2B genes expression (Nr3c1
nd Nr3c2) levels in the hippocampus of SC and IC groups. Each
xperimental animal group consists of 6–9 in behavioral assess-
ents, and 3 in molecular evaluation. Experimental design of the
tudy consisting of housing conditions, age, and number of animals
n each experiment, are summarized in Table 2..9. Statistical analysis
Comparison between the groups was analyzed using t-test and
ne-way ANOVA followed by Tukey’s post hoc test. P < 0.05 waslletin 121 (2016) 158–168
considered statistically signiﬁcant. The factors were housing [social
condition (SC) and isolation condition (IC)] and treatments [control:
no treatment and treatment: drug-administered animals] for all
assessments.
3. Results
3.1. Effects of juvenile SIS on mice behavior
In order to validate the applied SIS paradigm, SC and IC animals
were evaluated using behavioral tests including FST, splash test,
and EPM. Social isolation stress increased the immobility time in IC
mice compared with SC animals in the FST (t = 5.10, df = 14, P < 0.001,
Fig. 1a). In the splash test, SIS induced a signiﬁcant decline in groom-
ing activity time in IC mice in comparison with SC mice (t = 6.964,
df = 14, P < 0.001, Fig. 1b). In the EPM, percentage of spent time in
the open arms and percentage of open arms entries were evaluated
as variables relevant to anxiety-like behaviors. In comparison with
SC mice, SIS remarkably decreased percentage of spent time in the
open arms (t = 3.124, df = 14, P < 0.01, Fig. 1c) as well as percentage
of open arms entries (t = 4.598, df = 16, P < 0.001, Fig. 1d) in IC mice.
3.2. Juvenile SIS reduced clonic and tonic seizure thresholds in
PTZ model of seizures
Using PTZ model of seizures, SIS signiﬁcantly decreased the
seizure thresholds in IC mice. Data have revealed a signiﬁcant
difference between IC and SC animals in relation to both clonic
(t = 9.066, df = 14, P < 0.001, Fig. 2a) and tonic (t = 7.80, df = 10,
P < 0.001, Fig. 2b) seizure thresholds.
3.3. NMDA receptor antagonists reverse the proconvulsant effect
of juvenile SIS
Clonic and tonic seizure thresholds were determined for the dif-
ferent doses of NMDA antagonists including MK-801 and ketamine
in SC and IC mice. ANOVA analysis showed that there were sig-
niﬁcant differences between all treated groups in clonic (F(11,
84) = 11.11, P < 0.001, Fig. 3a) and tonic (F(11, 60) = 20.80, P < 0.001,
Fig. 3b) seizure thresholds. Fig. 3 presents signiﬁcant differences
in clonic and tonic seizure thresholds between IC and SC groups
as well as saline, MK-801 (0.01 mg/kg), and ketamine (0.1 mg/kg)
treated groups (***P < 0.001 for all). However, there was  no signiﬁ-
cant difference between SC and IC animals that were administered
with MK-801 (0.05 mg/kg), and ketamine (0.5 mg/kg) in both clonic
and tonic seizure thresholds (P > 0.05).
Tukey’s test showed that injection of ketamine (0.5 mg/kg)
signiﬁcantly reversed the proconvulsant effect of IC mice when
compared with IC saline-injected group in the both clonic
(##P < 0.01) and tonic (###P < 0.001) seizure thresholds. However,
administration the lower doses of ketamine (0.1 mg/kg) had no
signiﬁcant effect on the clonic and tonic seizure thresholds in IC
mice (P > 0.05). On the other hand, data have shown that MK-801
(0.05 mg/kg) signiﬁcantly increased the clonic and tonic seizure
thresholds in IC mice when compared with saline treated IC groups
in the both clonic (##P < 0.01) and tonic (#P  < 0.05) seizure mod-
els. However, lower dose of MK-801 (0.01 mg/kg) did not alter the
clonic and tonic seizure threshold in IC animals (P > 0.05). Also, none
of these treatments affected the clonic and tonice seizure thresh-
olds in SC mice (P > 0.05).
3.4. Nitrergic system contributes to anticonvulsant effect of
NMDA receptor antagonists in socially isolated animals
In the ﬁrst part we  try to investigate the possible effect of L-
NAME (non-selective NOS inhibitor) on the anticonvulsat effect
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Fig 1. Effect of different housing conditions, social condition (SC) and isolated condition (IC), on the immobility time in the FST (n = 8) (a), grooming activity time in the
splash  test (n = 8) (b), percentage of time spent in the open arm in the EPM (n = 8) (c), and percentage of open arm entries in the EPM (n = 9) (d). Values are expressed as the
mean  ± S.E.M. from 8 animals and were analyzed using t-test. **P < 0.01 and ***P < 0.001 compared with the SC group.
Fig. 2. Effect of different housing conditions, social condition (SC) and isolated condition (IC), on the colonic seizure (n = 8) (a), and tonic seizure (n = 6) (b) thresholds in the
PTZ-model of seizure. Values are expressed as the mean ± S.E.M. from 8 animals and were analyzed using t-test. ***P < 0.001 compared with the SC group.
Fig. 3. Effects of different housing conditions (social condition (SC) and isolated condition (IC)) and treatments; including saline, ketamine (0.1 and 0.5 mg/kg), MK-801 (0.01
and  0.05 mg/kg) on the clonic (n = 8) (a), and tonic (n = 6) (b) seizure thresholds in the PTZ-model of seizure. Values are expressed as the mean ± S.E.M. and were analyzed
using  one-way ANOVA followed by Tukey’s post hoc test. ***P < 0.001 compared with the SC saline treated group. #P < 0.05, ##P < 0.01, and ###P < 0.001 compared with the
IC  saline treated group.
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Fig. 4. Effects of different housing conditions (social condition (SC) and isolated condition (IC)) and treatments; including saline, L-NAME (LNM)(10 mg/kg), ketamine
(Ket)(0.1 mg/kg), MK-801 (MK)(0.01 mg/kg), and L-NAME (10 mg/kg) + ketamine (0.1 mg/kg)/MK-801 (0.01 mg/kg) co-treatments on the clonic (n = 8) (a), and tonic (n = 6)
(b)  seizure thresholds in the PTZ-model of seizure. Values are expressed as the mean ± S.E.M. and were analyzed using one-way ANOVA followed by Tukey’s post hoc test.
***P  < 0.001 compared with the SC saline treated group. #P < 0.05 and ###P < 0.001 compared with the IC saline treated group.
Fig. 5. Effects of different housing conditions (social condition (SC) and isolated condition (IC)) and treatments; including saline, Tween80 1%, 7-NI (15 mg/kg), ketamine (Ket)
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H0.1  mg/kg), MK-801 (MK) (0.01 mg/kg), and 7-NI (15 mg/kg) + ketamine (0.1 mg/kg
hresholds in the PTZ-model of seizure. Values are expressed as the mean ± S.E.M. a
ompared with the SC saline treated group. ##P < 0.01 and ###P < 0.001 compared
f NMDA antagonists in IC animals. One-way ANOVA analysis has
hown that there are signiﬁcant differences between the groups
n the clonic (F(13, 96) = 11.80, P < 0.001, Fig. 4a) and tonic (F(13,
0) = 25.63, P < 0.0001, Fig. 4b) seizure models. Fig. 4 indicates
hat there were signiﬁcant differences in the clonic and tonic
eizure thresholds between IC and SC controls as well as saline, L-
AME (10 mg/kg), ketamine (0.1 mg/kg), and MK-801 (0.01 mg/kg)
reated groups (***P < 0.001 for all groups). However, there was
o any signiﬁcant difference between SC and IC groups when
nimals were co-treated with L-NAME (10 mg/kg) and ketamine
0.1 mg/kg)/MK-801 (0.01 mg/kg) (P > 0.05).
Tukey’s test showed that co-administration of L-NAME and
etamine (#P  < 0.05 and ###P < 0.001) as well as co-treatment
f L-NAME and MK-801 (#P  < 0.05 and ###P < 0.001) signiﬁcantly
mproved the both clonic and tonic seizure thresholds of IC mice
hen compared to IC saline-treated group. None of these treat-
ents affected the clonic and tonic seizure thresholds in SC mice
P > 0.05).
In the next part, we evaluated the possible effect of 7-NI
selective nNOS inhibitor) on the anticonvulst effect of NMDA
ntagonists. One-way ANOVA analysis shows that there were
igniﬁcant differences between the groups in the clonic (F(16,
8) = 7.522, P < 0.001, Fig. 5a) and tonic (F(13, 70) = 21.07, P < 0.001,
ig. 5b) seizure thresholds. There were signiﬁcant differences in the
lonic and tonic seizure thresholds between IC and SC controls as
ell as saline, Tween80, 7-NI (15 mg/kg), ketamine (0.1 mg/kg), and
K-801 (0.01 mg/kg) treated groups (***P < 0.001 for all groups).
owever, there was no signiﬁcant difference between SC and801 (0.01 mg/kg) co-treatments on the clonic (n = 8) (a), and tonic (n = 6) (b) seizure
ere analyzed using one-way ANOVA followed by Tukey’s post hoc test. ***P < 0.001
he IC saline treated group.
IC animals in 7-NI (10 mg/kg) and ketamine (0.1 mg/kg)/MK-801
(0.01 mg/kg) co-administered groups (P > 0.05).
Tukey’s test showed that co-injection of 7-NI and Ketamine
(##P < 0.01 and ###P < 0.001) as well as co-treatment of 7-NI and
MK-801 (##P < 0.01 and ###P < 0.001) signiﬁcantly enhanced the
clonic and tonic seizure thresholds of IC mice when compared to IC
Tween80/saline-treated group. None of these treatments affected
the clonic and tonic seizure thresholds in SC mice (P > 0.05).
3.5. Juvenile SIS up regulates the NR2B but not NR2A subunit of
NMDA receptor in the hippocampus
Fig. 6 shows the effects of juvenile SIS on expression of NMDA
receptors genes. t-test analysis demonstrated the over-expression
of NR2B (t = 22.38, df = 4, P < 0.001) in hippocampus of IC mice in
comparison with SC animals. However, no signiﬁcant change in
expression of NR2A was observed in IC mice when compared to SC
mice (t = 0.4554, df = 4, P > 0.05). In addition, there was  no signiﬁcant
effect of housing conditions (SC and IC) on hprt1 expression.
4. Discussion
Results of the current study showed that experiencing SIS in the
early adolescence increased seizure susceptibility to PTZ and also,
altered NMDA receptor structure in the hippocampus. We  demon-
strated that increase in the seizure vulnerability was  associated
to alterations in NMDA/NO regulation in the hippocampus of IC
animals. Unlike SC mice, administration of non-effective doses of
S. Amiri et al. / Brain Research Bu
Fig. 6. Effect of different housing conditions, social condition (SC) and isolated con-
dition (IC) on NMDA receptor subunits (NR2A and NR2B) gene expression in the
hippocampus of animals. Values are expressed as the mean ± S.E.M. and were ana-
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olumns.
MDA receptor antagonists (ketamine and MK-801) reversed the
roconvulsant effects of SIS in IC mice. We  found that increased
xpression of NMDA receptor subunit NR2B following 4 weeks of SIS
ay  account for increased seizure susceptibility to PTZ by enhanc-
ng the NMDA/NO pathway in the hippocampus.
Applying animal models of chronic stress has been suggested
s useful tools to investigate the underlying mechanisms through
hich, stress exerts its detrimental effects on the brain and behav-
or (Blanchard et al., 2001). Although there are recent studies
hich have focused on the inﬂuence of chronic stress on seizure
ctivity (Salzberg et al., 2007; Russo et al., 2013; MacKenzie and
aguire, 2015) underpinning mechanisms by which social envi-
onment affects the seizure susceptibility have not been well
tudied. Accumulating evidence indicates that exposure to early
ife stress during developmental stages of brain engages in shap-
ng of vast majority of brain disorders including seizures (Lupien
t al., 2009; Huang, 2014). In this context, juvenile SIS has been
hown to induce long lasting cellular and molecular alterations
n development of cortico-limbic regions (Andersen and Teicher,
008) and primes seizure occurrence in adulthood (Matsumoto
t al., 2003; Amiri et al., 2014). Several lines of research indicate
hat imbalance between excitatory and inhibitory neurotransmis-
ion contributes to pathophysiology of seizure disorders (Zˇiburkus
t al., 2013). Our results showed that juvenile SIS-induced seizure
usceptibility to PTZ accompanied with anxiety and depressive-
ike behaviors. These results are consistent with previous studies
hich have reported that adolescent SIS not only is able to render
eizure occurrence but also, provokes anxiety and depressive-like
ehaviors in adult animals (Chadda and Devaud, 2004; Matsumoto
t al., 2003; Amiri et al., 2014). We  recently demonstrated that
lockade of NMDA receptors by subeffective doses of ketamine
nd MK-801 could reverse the depressive-like behaviors following
dolescent SIS (Salzberg et al., 2007; Haj-Mirzaian et al., 2015a).
revious studies have reported that SIS negatively makes changes
n various neurotransmission systems including both nitrergic and
lutamatergic systems in the brain (Zhao et al., 2009; Gan et al.,
014). Furthermore, a recent study by Frasca et al., (2011) has
evealed that misplacement of NMDA receptors in the limbic area
rovokes excitatory state and epileptogenesis. Administration of
MDA receptor antagonists has been reported to have potent anti-
onvulsant properties in the literature (Ghasemi and Schachter,
011; Fujikawa, 2005). In consistence with previous reports, treat-
ng IC mice with subeffective doses of both ketamine and MK-801,
s non-comparative NMDA receptor antagonists, increased both
lonic and tonic seizure thresholds in IC animals. However, samelletin 121 (2016) 158–168 167
treatments to socially housed counterparts did not change the
seizure threshold.
Previous research has shown that SIS increases the NMDA
receptors in the hippocampus (Chang et al., 2015) and NMDA
receptor binding capacity in the frontal cortex (Toua et al., 2010).
Also, metabotropic glutamate receptors (mGluRs) were reported to
undergo functional changes in socially isolated animals (Kawasaki
et al., 2011). Moreover, up-regulation of NMDA receptor sub-
units such as NR2A in the prefrontal cortex (Turnock Jones et al.,
2009) along with NR2A and NR2B in the hippocampus (Zhao et al.,
2009) was  reported in previous studies. Thus, it is possible that
abnormal activity of glutamatergic system plays a part in the pro-
convulsant effect of juvenile SIS. To support this, we  found that
juvenile SIS increased expression of NR2B (but not NR2A) subunit
of NMDA receptor in the hippocampus. Our results were in line
with recent ﬁndings demonstrating that SIS increases the expres-
sion of NR2A and NR2B subunits of NMDA receptors in the different
regions of the brain such as hippocampus and cortical areas (Chang
et al., 2015; Turnock Jones et al., 2009). It has been well docu-
mented that NR2B subunit of NMDA receptor is potently involved
in several (patho) physiological processes such as developmental
plasticity and epilepsy (Frasca et al., 2011; Ewald et al., 2008; Di
Maio et al., 2013). In this context, ample evidence indicates that
NR2B subunit of NMDA receptor is responsible for massive cal-
cium inﬂux into postsynaptic hippocampal neurons that results in
hyper-excitability and activation of diversity of biological pathways
including nitrergic system (Forder and Tymianski, 2009). These
results indicate that NR2B NMDA receptor subunit is involved in
the proconvulsant effect of juvenile SIS in IC mice. Large body of
evidence suggests that nitrergic system participates in the patho-
physiology of seizure disorders (Watanabe et al., 2013; Przegalin˜ski
et al., 1996). Also, there are pieces of evidence indicating that inhi-
bition of NOS (mostly nNOS) by NOS inhibitors such as L-NAME and
7NI exerted anticonvulsant effects in experimental studies (Banach
et al., 2011). It is well accepted that activation of NMDA receptors
is associated with an increase in the NO production through activa-
tion of nNOS (Sattler et al., 1999). Recently, we showed that juvenile
SIS-induced increase in hippocampal NO was correlated with an
increase in seizure susceptibility to PTZ. In this regard, results of
this study showed that co-administration of subeffective doses of
NMDA receptor antagonists (ketamine and MK-801) along with L-
NAME or 7NI potently reversed the proconvulsant effect of SIS by
increasing both clonic and tonic seizure thresholds in IC mice. How-
ever, such effects were not observed in SC mice treated with 7NI or
L-NAME alone or in combination with NMDA receptor antagonists.
These results suggest that enhanced seizure susceptibility to PTZ
in IC mice is partially related to enhanced activation of NMDA/NO
pathway mainly through interaction of NR2B and nNOS. Also, these
changes in the structure and function of NMDA receptors have been
shown to have negative effects on emotional state of mice (Chang
et al., 2015). However, further studies are needed to determine
whether other neurotransmission abnormalities are involved in the
proconvulsant effect of SIS. For instance, it has been reported that
opioidergic and GABAergic system may  be involved in the procon-
vulsant effect of post weaning SIS (Matsumoto et al., 2003; Khan
et al., 2015). Considering that experiencing chronic psychosocial
stress during adolescence is regarded as a serious risk for develop-
ment of mental difﬁculties in females (Andersen and Teicher, 2008),
effects of juvenile SIS on developing brain and initiation of seizure
disorders have not been well studied in female animals (Jones et al.,
2014).
In conclusion, results of our study showed that behav-increased susceptibility to PTZ-induced seizures and, dysfunction
of NMDA/NO pathway through NR2B overexpression may  play a
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ole in the negative impact of SIS on the both tonic and clonic
eizure thresholds.
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